Pfizer Ltd
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India.[1]
It is the 3rd largest multinational pharmaceutical company in India.[2]
- Market Cap ₹ 19,438 Cr.
- Current Price ₹ 4,249
- High / Low ₹ 6,453 / 3,701
- Stock P/E 127
- Book Value ₹ 302
- Dividend Yield 0.82 %
- ROCE 27.2 %
- ROE 19.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 33.2%
Cons
- Stock is trading at 14.1 times its book value
- Earnings include an other income of Rs.512 Cr.
- Working capital days have increased from 60.8 days to 135 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE 500 Nifty Smallcap 250 BSE Healthcare Nifty 500 Nifty 500 Multicap 50:25:25
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| 664 | 676 | 678 | |
| 537 | 815 | 760 | |
| Operating Profit | 127 | -139 | -82 |
| OPM % | 19% | -21% | -12% |
| 48 | 600 | 512 | |
| Interest | 0 | 0 | 0 |
| Depreciation | 13 | 10 | 11 |
| Profit before tax | 163 | 451 | 419 |
| Tax % | 35% | 25% | 29% |
| 106 | 340 | 300 | |
| EPS in Rs | 35.64 | 113.94 | 100.39 |
| Dividend Payout % | 63% | 24% | 12% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -3% |
| 3 Years: | 0% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Equity Capital | 30 | 30 | 30 |
| Reserves | 376 | 620 | 871 |
| 0 | 0 | 0 | |
| 240 | 218 | 197 | |
| Total Liabilities | 646 | 867 | 1,098 |
| 65 | 60 | 51 | |
| CWIP | 2 | 10 | 32 |
| Investments | 0 | 0 | 0 |
| 579 | 797 | 1,014 | |
| Total Assets | 646 | 867 | 1,098 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| 123 | 17 | 238 | |
| 7 | 232 | -79 | |
| -34 | -76 | -95 | |
| Net Cash Flow | 97 | 173 | 64 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Nov 2006 | Nov 2007 | Nov 2008 | |
|---|---|---|---|
| Debtor Days | 38 | 33 | 32 |
| Inventory Days | 160 | 149 | 190 |
| Days Payable | 208 | 144 | 164 |
| Cash Conversion Cycle | -10 | 39 | 58 |
| Working Capital Days | 2 | 45 | 135 |
| ROCE % | 37% | 27% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
11 Apr - Certificate dated April 11, 2025 issued by KFin Technologies Limited for the quarter ended March 31, 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
1 Apr - Resignation of Senior Director – Compliance, effective May 13, 2025.
- Closure of Trading Window 31 Mar
-
Update On Transfer And Assignment Of Pfizer'S Unexpired Leasehold Rights In The Land Situated At Plot No. 16, Trans Thane Creek Industrial Area, Turbhe, Thane And Sale Of
Structures And Buildings Constructed Thereon, To Zoetis Pharmaceutical Research Private Limited
29 Mar - Pfizer transfers leasehold rights and buildings to Zoetis for Rs. 264.40 Crores.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 19 Mar
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from nse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
Concalls
-
Aug 2020TranscriptPPT
-
May 2017TranscriptPPT
-
Feb 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Aug 2016TranscriptPPT
-
May 2016TranscriptPPT
-
Feb 2016TranscriptPPT
Parentage
The company is a subsidiary of Pfizer Inc. one of the world’s leading biopharma companies with a presence in over 125 countries. Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. [1] [2]